In vitro and in vivo Antiallergic Effects of Taurine on Allergic Rhinitis

Background:The current treatment for allergic rhinitis (AR) is inadequate.Objective:The present study aimed to investigate the therapeutic effect of taurine on AR and to identify the underlying molecular mechanisms.Methods:The serum level of the antioxidant enzyme extracellular superoxide dismutase (SOD3) was determined in AR patients and in healthy controls. The antiallergic inflammatory effects of taurine were evaluated in a dinitrophenyl-human serum albumin (DNP-HSA)-stimulated human mast cell line (HMC-1) and in an ovalbumin (OVA)-induced AR mouse model.Results:Clinically, a reduction in serum level of SOD3 was observed in AR patients. Taurine treatment led to dose-dependent increases in SOD3 at both protein and mRNA levels in HMC-1 cells. SOD3 production was regulated by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) in response to taurine. SOD3 overexpression inhibited the release of proinflammatory cytokines including tumor necrosis factor-alpha (, interleukin (IL)-4, and IL-6. Its overexpression also ameliorated the loss of interferon-gamma. SOD3 and PPAR-gamma influenced inflammatory cytokine production via regulation of the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2). An OVA-induced AR animal model study showed that taurine was efficacious in alleviating allergic inflammatory reactions by relieving behavior symptoms of AR mice and reducing eosinophilic and mast cell infiltration into the nasal cavity. In addition, taurine treatment increased the production of SOD3 and PPAR-gamma, which, in turn, suppressed expression of proinflammatory cytokines through phosphorylation of ERK1/2.Conclusion:Taurine could potentially serve as a therapeutic treatment for allergic disorders. (c) 2020 S. Karger AG, Basel